Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis
Authors
Keywords
-
Journal
Protein & Cell
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-08
DOI
10.1007/s13238-020-00809-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action
- (2020) Milton Packer DIABETES CARE
- Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium–glucose cotransporter 2 inhibitors
- (2020) Milton Packer EUROPEAN JOURNAL OF HEART FAILURE
- Upregulation of Rubicon promotes autosis during myocardial ischemia/reperfusion injury
- (2020) Jihoon Nah et al. JOURNAL OF CLINICAL INVESTIGATION
- Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats
- (2019) Rachel J. Perry et al. Nature Communications
- Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction
- (2019) Salva R. Yurista et al. EUROPEAN JOURNAL OF HEART FAILURE
- Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
- (2019) Carlos G. Santos-Gallego et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial
- (2019) Michael E. Nassif et al. CIRCULATION
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reinterpreting Cardiorenal Protection of Renal Sodium–Glucose Cotransporter 2 Inhibitors via Cellular Life History Programming
- (2019) Angelo Avogaro et al. DIABETES CARE
- The Role of Autophagy in the Heart
- (2018) Sebastiano Sciarretta et al. Annual Review of Physiology
- Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
- (2018) Lorenzo Galluzzi et al. CELL DEATH AND DIFFERENTIATION
- New Insights Into the Role of mTOR Signaling in the Cardiovascular System
- (2018) Sebastiano Sciarretta et al. CIRCULATION RESEARCH
- Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes
- (2018) Sean L. Zheng et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Trehalose-Induced Activation of Autophagy Improves Cardiac Remodeling After Myocardial Infarction
- (2018) Sebastiano Sciarretta et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes
- (2018) Stephen J. Greene et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of glucose-lowering therapies on heart failure
- (2018) Michael Nassif et al. Nature Reviews Cardiology
- Cardioprotective effects of autophagy: Eat your heart out, heart failure!
- (2018) Gaetano Santulli Science Translational Medicine
- LncRNA CAIF inhibits autophagy and attenuates myocardial infarction by blocking p53-mediated myocardin transcription
- (2018) Cui-Yun Liu et al. Nature Communications
- SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection
- (2018) Robert M Bell et al. Lancet Diabetes & Endocrinology
- OUP accepted manuscript
- (2018) EUROPEAN HEART JOURNAL
- Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes
- (2018) Thomas A. Zelniker et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
- (2018) Peter Ueda et al. BMJ-British Medical Journal
- Myocardial stress and autophagy: mechanisms and potential therapies
- (2017) Lea M. D. Delbridge et al. Nature Reviews Cardiology
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure
- (2017) Milton Packer et al. JAMA Cardiology
- Empagliflozin’s Fuel Hypothesis: Not so Soon
- (2016) Gary D. Lopaschuk et al. Cell Metabolism
- Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
- (2016) Sunder Mudaliar et al. DIABETES CARE
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
- (2016) Antonius Baartscheer et al. DIABETOLOGIA
- Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor
- (2015) Y. Xiang et al. BLOOD
- Autophagy in cardiovascular biology
- (2015) Sergio Lavandero et al. JOURNAL OF CLINICAL INVESTIGATION
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
- (2015) Jennifer B. Green et al. NEW ENGLAND JOURNAL OF MEDICINE
- I-TASSER server: new development for protein structure and function predictions
- (2015) Jianyi Yang et al. NUCLEIC ACIDS RESEARCH
- Possible adverse effects of SGLT2 inhibitors on bone
- (2015) Simeon I Taylor et al. Lancet Diabetes & Endocrinology
- Histone Deacetylase Inhibition Blunts Ischemia/Reperfusion Injury by Inducing Cardiomyocyte Autophagy
- (2014) Min Xie et al. CIRCULATION
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Autosis is a Na+,K+-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia
- (2013) Y. Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Suppression of autophagy is protective in high glucose-induced cardiomyocyte injury
- (2012) Satoru Kobayashi et al. Autophagy
- Cell Death in the Pathogenesis of Heart Disease: Mechanisms and Significance
- (2010) Russell S. Whelan et al. Annual Review of Physiology
- Deacetylation of FoxO by Sirt1 Plays an Essential Role in Mediating Starvation-Induced Autophagy in Cardiac Myocytes
- (2010) Nirmala Hariharan et al. CIRCULATION RESEARCH
- Role of BNIP3 and NIX in cell death, autophagy and mitophagy
- (2009) J Zhang et al. CELL DEATH AND DIFFERENTIATION
- Activation of Na + /H + Exchanger 1 Is Sufficient to Generate Ca 2+ Signals That Induce Cardiac Hypertrophy and Heart Failure
- (2008) Tomoe Y. Nakamura et al. CIRCULATION RESEARCH
- 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
- (2008) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now